0000000000134076

AUTHOR

Antonio Toscano

showing 10 related works from this author

The serum level of free testosterone is reduced in amyotrophic lateral sclerosis

2002

Sporadic amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting upper and lower motoneurons. There is an approximately 2:1 higher incidence of ALS in men compared to women, and this has raised the hypothesis of an involvement of sex hormones in the etiopathogenesis of the disorder. In this work, the serum levels of dehydroepiandrosterone sulphate (DHEAS), 17-betaestradiol, free and total testosterone were measured in 35 patients with defined or probable ALS, according to the El-Escorial/WFN revisited criteria, and compared to those obtained from 57 disease controls, matched for age and gender to the ALS group. We found no differences between ALS cases and …

Malemedicine.medical_specialtyCentral nervous system diseaseDehydroepiandrosterone sulphateDegenerative diseaseSex hormone-binding globulinInternal medicinemedicineHumans17-βestradiol; Amyotrophic lateral sclerosis; Dehydroepiandrosterone sulphate; Motoneurons; Sex hormone binding globulin; TestosteroneTestosteroneAmyotrophic lateral sclerosisAged17-βestradiolAged 80 and overSex Characteristicsbiologybusiness.industryTestosterone (patch)Middle Agedmedicine.diseaseAmyotrophic lateral sclerosisPathophysiologySex hormone binding globulinMotoneuronsEndocrinologyNeurologybiology.proteinFemaleNeurology (clinical)businessSex characteristicsHormone
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Enterococcal meningitis caused by Enterococcus casseliflavus. First case report

2005

Abstract Background Enterococcal meningitis is an uncommon disease usually caused by Enterococcus faecalis and Enterococcus faecium and is associated with a high mortality rate. Enterococcus casseliflavus has been implicated in a wide variety of infections in humans, but never in meningitis. Case presentation A 77-year-old Italian female presented for evaluation of fever, stupor, diarrhea and vomiting of 3 days duration. There was no history of head injury nor of previous surgical procedures. She had been suffering from rheumatoid arthritis for 30 years, for which she was being treated with steroids and methotrexate. On admission, she was febrile, alert but not oriented to time and place. H…

BACTEREMIACase ReportMicrobial Sensitivity TestsVANCOMYCIN-RESISTANT ENTEROCOCCI; CLINICAL-FEATURES; BACTEREMIA; GALLINARUM; MOTILE ENTEROCOCCUS; OUTCOMESMeropenemEnterococcus faecalisVANCOMYCIN-RESISTANT ENTEROCOCCIlcsh:Infectious and parasitic diseaseslaw.inventionMicrobiologyMeningitis BacteriallawAmpicillinmedicineEnterococcus casseliflavusHumanslcsh:RC109-216Gram-Positive Bacterial InfectionsAgedCerebrospinal FluidOUTCOMESSigmoid Diseasesbiologybusiness.industryCLINICAL-FEATURESMeropenembiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsMOTILE ENTEROCOCCUSInfectious DiseasesGram stainingEnterococcusSulbactamGALLINARUMAmpicillinFemaleThienamycinsbusinessMeningitisEnterococcusmedicine.drugEnterococcus faeciumBMC Infectious Diseases
researchProduct

Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy.

2019

Background and purpose The aim was to assess the value of insoluble PABPN1 muscle fibre nuclei accumulation in the diagnosis of atypical cases of oculopharyngeal muscular dystrophy (OPMD). Methods Muscle biopsies from a selected cohort of 423 adult patients from several Italian neuromuscular centres were analysed by immunofluorescence: 30 muscle biopsies of genetically proven OPMD, 30 biopsies from patients not affected by neuromuscular disorders, 220 from genetically undiagnosed patients presenting ptosis or swallowing disturbances, progressive lower proximal weakness and/or isolated rimmed vacuoles at muscle biopsy and 143 muscle biopsies of patients affected by other neuromuscular diseas…

Pathologymedicine.medical_specialtyFluorescent Antibody TechniquePoly(A)-Binding Protein IOculopharyngeal muscular dystrophy03 medical and health sciences0302 clinical medicinePtosisMuscular Dystrophy OculopharyngealPABPN1 accumulations; PABPN1 immunofluorescence; oculopharyngeal musclular dystrophy; rimmed vacuoles; tubulofilamentous intranuclear inclusionsmedicineHumans030212 general & internal medicineMuscle fibreMuscle SkeletalCell NucleusMuscle biopsymedicine.diagnostic_testbusiness.industryExternal ophthalmoplegiaRimmed vacuolesmedicine.diseaseNeurologyCohortNeurology (clinical)Inclusion body myositismedicine.symptombusiness030217 neurology & neurosurgeryEuropean journal of neurologyReferences
researchProduct

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

2015

Abstract Background: Familial amyloid polyneuropathy related to transthyretin gene (TTR-FAP) is a life-threatening disease transmitted as an autosomal dominant trait. Val30Met mutation accounts for the majority of the patients with large endemic foci especially in Portugal, Sweden and Japan. However, more than one hundred other mutations have been described worldwide. A great phenotypic variability among patients with late- and early-onset has been reported. Objective: To present a detailed report of TTR-FAP patients diagnosed in our tertiary neuromuscular center, in a 20-year period. Methods: Clinical informations were gathered through the database of our center. Results: The study involve…

Research ReportPediatricsmedicine.medical_specialtyPathologydysautonomiaCardiomyopathyLate onsetTTRtransthyretinmedicineFamilial amyloid polyneuropathy FAP transthyretin TTR amyloidosis cardiomyopathy dysautonomia epidemiology Italyamyloidosisbiologybusiness.industryAmyloidosisDysautonomiaAutosomal dominant traitFAPmedicine.diseaseTransthyretinPeripheral neuropathyNeurologyItalyFamilial amyloid polyneuropathybiology.proteinepidemiologyNeurology (clinical)medicine.symptombusinessPolyneuropathycardiomyopathyJournal of Neuromuscular Diseases
researchProduct

Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis

2018

Background and purpose Late-onset Pompe disease (LOPD) is a rare, multisystem disorder that is well established to mainly impair skeletal muscle function. Systematic studies exploring brain functions in LOPD are lacking. The aim of this study was to detect morphological and functional brain alterations as well as neuropsychological impairment in LOPD. Methods We studied 21 patients (10 male, mean age 49 ± 18.4 years) with defined diagnosis of LOPD, divided into two groups: one with pre-symptomatic hyperCKemia with no muscle weakness and the second with limb-girdle muscle weakness. All patients underwent 3T magnetic resonance imaging (MRI) to obtain morphological/angiographic evaluation as w…

AdultMalemedicine.medical_specialtyAdolescentSmoker scoreNeuropsychological Testscerebrovascular abnormalitieslate-onset Pompe diseaseYoung Adult03 medical and health sciences0302 clinical medicineAtrophyNeuroimagingInternal medicineConnectomemedicinecerebrovascular abnormalities Fazekas score functional magnetic resonance imaging late-onset Pompe disease Pompe disease Smoker score Neurology Neurology (clinical)HumansCognitive Dysfunction030212 general & internal medicineNeuropsychological assessmentAge of OnsetGray MatterAgedmedicine.diagnostic_testGlycogen Storage Disease Type IIbusiness.industryMuscle weaknessPompe diseaseMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance Imagingfunctional magnetic resonance imagingHyperintensityFazekas scoreSuperior frontal gyrusNeurologyBrain sizeCardiologyFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onse…

2018

Background: Primary aim was to investigate the diagnostic value of PAS-positive vacuolated lymphocytes on blood smear in Late Onset Pompe Disease (LOPD) patients and, secondly, to evaluate its potential utility in monitoring treatment effects.Methods: We examined blood smear of 26 LOPD patients. We evaluated 10 treated and 16 untreated LOPD patients. Among the latter group, 7 patients later initiated ERT and were tested again 6 months after start. Blood smear was also sampled from 82 controls and 19 patients with other muscle glycogenoses (MGSDs). PAS staining was used to evaluate: (1) presence of lymphocytes with glycogen-filled vacuoles, (2) quantification of vacuolated lymphocytes.Result…

0301 basic medicinemedicine.medical_specialtytherapeutic monitoringBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoring; Neurology; Neurology (clinical)Late onsetPeriodic acid–Schiff stainDiseasePAS-positive lymphocytesGastroenterologylcsh:RC346-429Vacuolated Lymphocytes03 medical and health sciences0302 clinical medicineInternal medicineBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoringmedicineScreening toolLOPD screening testlcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryPompe diseasePredictive value030104 developmental biologyBlood smearNeurologyblood smearBiomarker (medicine)Neurology (clinical)business030217 neurology & neurosurgeryFrontiers in neurology
researchProduct

Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area

2021

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis, followed by liver tra…

Tafamidismedicine.medical_specialtySurvivalmedicine.medical_treatmentHereditary transthyretin amyloidosisNeurosciences. Biological psychiatry. NeuropsychiatryDisease030204 cardiovascular system & hematologyLiver transplantationArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-V30MInternal medicineATTRvPolyneuropathyMedicineATTRv; hereditary transthyretin amyloidosis; inotersen; non-V30M; patisiran; polyneuropathy; survival; tafamidis; patisiran; inotersenbiologybusiness.industryGeneral NeuroscienceAmyloidosisMedical recordmedicine.diseaseTafamidisTransthyretinchemistryCohortbiology.proteinPatisiranSettore MED/26 - NeurologiabusinessPolyneuropathy030217 neurology & neurosurgeryRC321-571Inotersen
researchProduct

Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patients with long-term follow-up in two.

2009

We report seven patients with immune-mediated rippling muscle disease (iRMD) and AChR-antibody positive myasthenia gravis (MG) without germline caveolin-3 gene mutations. We describe the follow-up of two patients and the clinical features of five new patients (1 female, 4 male, aged 32 to 69 years). These presented with significant generalized, exercise-induced and electrically-silent muscle rippling with myalgia, combined with generalized MG. In two of the seven patients, MG appeared before iRMD. Mediastinal imaging excluded thymic alterations in all, although two had other coincident tumours. Myalgia and rippling were aggravated by acetylcholinesterase-inhibitor treatment. Generalized MG …

myalgiaAdultMalePathologymedicine.medical_specialtyCaveolin 3Immunogenicmedicine.medical_treatmentMuscle Fibers SkeletalMuscle ProteinsCaveolin-3; Immunogenic; Myasthenia gravis; Rippling muscle disease; TherapyAzathioprineThymus GlandGene mutationBiologyCaveolaeDysferlinCaveolin-3Muscular DiseasesAzathioprineMyasthenia GravismedicineHumansMuscle SkeletalGenetics (clinical)AgedAutoantibodiesSarcolemmaElectromyographyAutoantibodyRippling muscle diseasePlasmapheresisMiddle Agedmedicine.diseaseMyasthenia gravisNeurologyPediatrics Perinatology and Child Healthbiology.proteinPlasmapheresisFemaleSteroidsTherapyNeurology (clinical)Cholinesterase Inhibitorsmedicine.symptommedicine.drugFollow-Up StudiesMuscle ContractionNeuromuscular disorders : NMD
researchProduct

Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Ita…

2020

Background and purpose: The role of lifestyle and dietary habits and antecedent events has not been clearly identified in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods: Information was collected about modifiable environmental factors and antecedent infections and vaccinations in patients with CIDP included in an Italian CIDP Database. Only patients who reported not having changed their diet or the lifestyle habits investigated in the study after the appearance of CIDP were included. The partners of patients with CIDP were chosen as controls. Gender-matched analysis was performed with randomly selected controls with a 1:1 ratio of patients and controls. Results: D…

AdultMalemedicine.medical_specialtylifestyleDatabases FactualDiseasecomputer.software_genreSettore MED/26chronic inflammatory demyelinating neuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; diet; epidemiology; infections; lifestyle; vaccination03 medical and health sciences0302 clinical medicineRisk FactorsEpidemiologymedicineHumans030212 general & internal medicineinfectionsRisk factorChildLife Stylechronic inflammatory demyelinating polyradiculoneuropathyDatabasebusiness.industryAntecedent variablechronic inflammatory demyelinating neuropathyPolyradiculoneuropathyFeeding BehaviorMiddle Agedmedicine.diseasevaccinationinfectionSettore MED/26 - NEUROLOGIAAntecedent (behavioral psychology)ItalyPolyradiculoneuropathy Chronic Inflammatory DemyelinatingNeurologyFemaleepidemiologyNeurology (clinical)ComplicationbusinessLifestyle habitsdietcomputer030217 neurology & neurosurgery
researchProduct